Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 2b/3, Multicentre, Randomised, Open, Controlled Study on the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB) Implantation in Non-Infected Hypotrophic Non-Union Fractures

Next Previous
Trial Profile

A Pivotal Phase 2b/3, Multicentre, Randomised, Open, Controlled Study on the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB) Implantation in Non-Infected Hypotrophic Non-Union Fractures

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 27 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous osteoblastic cell therapy Bone Therapeutics (Primary)
  • Indications Non-union fracture
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioSenic

    • Most Recent Events

    • 03 Jul 2019 Status changed from active, no longer recruiting to discontinued.
    • 24 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
    • 19 Dec 2017 Status of trial is kept as active not recruiting as per investigators reply mentioning that competent authorities have been notified of the termination of the PREOB NU3 trial. As post treatment long-term safety follow-up is on-going, CT.gov status is active not recruiting. Patient still have to pass visit for safety purpose (last visit planned around April 2018). The study is effectively terminated for efficacy purpose since the last treated patient had the last efficacy visit.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top